Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
10x Genomics, Inc. (TXG) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-06-30, revenue was 616.9m $, net income was -75.1m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
10x Genomics, Inc. (TXG) is a company in the Health care sector; its shares trade on Nasdaq.
The price of 10x Genomics, Inc. (TXG) on November 2, 2026 is 63.94 $, −8.80 % on the day. Over 52 weeks the stock traded between 11.62 $ and 102.81 $; the price now sits 57 % of the way up that range. Over the past year the price changed by +508.83 %. Market capitalization is 8.77 billion $, rank 9 among 23 stocks of the same industry with a known capitalization.
10x Genomics, Inc. trades on Nasdaq under the ticker TXG. The company belongs to the Health care sector. The trading history on this page starts on 12 September 2019.
Over the past 52 weeks TXG has traded between 11.62 $ and 102.81 $. As of 2 November 2026 the price stood 66.64 % of the way from the 52-week low to the high.
Over one year TXG shares rose 508.83 %; over six months they rose 186.81 %. Volatility over 90 days is 79.33 %. Dividends are not included: this is price change only, as of 2 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 14.2, above the sector median of 3.6. Price to book is 10.6, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
10x Genomics, Inc. reported revenue of 617M $ and a net loss of 75M $ over the last four quarters. Net margin is −12.18 %. Revenue changed by −4.28 % year over year. Earnings per share are −0.59 $. Market capitalisation is 8.8B $.
TXG has a return on equity of −9.10 %, above the sector median of −40.58 %. Return on assets is −7.29 %, above the sector median of −30.08 %. Operating margin is −14.33 %, above the sector median of −20.96 %.